Affini-T Therapeutics is developing specific TCR-based immunotherapies for solid tumors using two complementary therapeutic modalities: Autologous TCR-T cell therapies and bispecific T Cell Engagers
Affini-T Therapeutics is developing specific TCR-based immunotherapies for solid tumors using two complementary therapeutic modalities: Autologous TCR-T cell therapies and bispecific T Cell Engagers. The company leverages high-throughput screening, synthetic biology, and gene editing technologies to target oncogenic driver mutations.
Affini-T Therapeutics is developing specific TCR-based immunotherapies for solid tumors using two complementary therapeutic modalities: Autologous TCR-T cell therapies and bispecific T Cell Engagers
Affini-T Therapeutics is developing specific TCR-based immunotherapies for solid tumors using two complementary therapeutic modalities: Autologous TCR-T cell therapies and bispecific T Cell Engagers. The company leverages high-throughput screening, synthetic biology, and gene editing technologies to target oncogenic driver mutations.